News

Novartis unit Sandoz is seeking approval for the similar indication as the reference product. The company’s marketing authorization application is supported by three pivotal clinical trials, which demonstrate

A planned interim analysis of Janus 1 phase 3 study showed that ruxolitinib plus capecitabine did not demonstrate a sufficient level of efficacy to warrant continuation. The primary

The Renal Pre-Competitive Consortium (RPC2) will develop and utilize large-scale data exploration to find new treatment targets for CKD. It will combine the R&D expertise of the pharmaceutical

Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed

The FDA has agreed with Cellceutix’s plan to initiate such a trial, and based upon the data from the Phase 1 trial, that the administration of Kevetrin doses

The revefenacin Phase 3 program, which includes two replicate efficacy studies and a single twelve-month long-term safety study, is designed to support the registration of the product in

The selected solutions include Oracle Siebel Clinical Trial Management System and Oracle Health Sciences Clinical Development Analytics. Oracle Siebel Clinical Trial Management System allows global clinical organizations to

The company seeks to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations, which are expected to be available in April this year. The new

Mylan will pay SEK165 per share, bringing the total value of the deal to $9.9bn including Meda’s debt. The transaction is anticipated to close by the end of